Bolt Biotherapeutics (BOLT) Income from Continuing Operations (2020 - 2026)
Bolt Biotherapeutics (BOLT) posted Income from Continuing Operations of 8648000.0 for Q1 2026, down 0.93% sequentially from 8568000.0 in Q4 2025, and up 29.71% YoY from 6666979.45 in Q1 2025.
Bolt Biotherapeutics (BOLT) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Bolt Biotherapeutics has reported Income from Continuing Operations for 7 years, with the latest figure at 8648000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 29.71% year-over-year to 8648000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 100047000.0 (down 41.02% YoY) and the FY2025 annual result came in at 137210000.0, up 19.22% from the prior year.
- Income from Continuing Operations fell to 8648000.0 in Q1 2026 per BOLT's latest filing, from 8568000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 8568000.0 in Q4 2025 and troughed at 58242000.0 in Q2 2022.
- A 5-year average of 30334235.29 and a median of 21497000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations surged 66.69% in 2024, then plunged 140.89% in 2025.
- Over 5 years, Income from Continuing Operations stood at 21497000.0 in 2022, then soared by 44.92% to 11840000.0 in 2023, then slumped by 73.61% to 20555000.0 in 2024, then jumped by 58.32% to 8568000.0 in 2025, then fell by 0.93% to 8648000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 8648000.0, 8568000.0, and 40070000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Bolt Biotherapeutics | 6.10 Mn | 6.10 Mn | - | -8.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -37.06 Mn |
| Mar 31, 2026 | -8.65 Mn |
| Dec 31, 2025 | -8.57 Mn |
| Sep 30, 2025 | -40.07 Mn |
| Jun 30, 2025 | -42.76 Mn |
| Mar 31, 2025 | -12.30 Mn |
| Dec 31, 2024 | -20.56 Mn |
| Sep 30, 2024 | -16.63 Mn |
| Jun 30, 2024 | -21.45 Mn |
| Mar 31, 2024 | -16.69 Mn |
| Dec 31, 2023 | -11.84 Mn |
| Sep 30, 2023 | -48.88 Mn |
| Jun 30, 2023 | -51.77 Mn |
| Mar 31, 2023 | -50.09 Mn |
| Dec 31, 2022 | -21.50 Mn |
| Sep 30, 2022 | -57.78 Mn |
| Jun 30, 2022 | -58.24 Mn |
| Mar 31, 2022 | -27.91 Mn |
| Dec 31, 2021 | -28.99 Mn |
| Sep 30, 2021 | -62.94 Mn |